Ge Y - Search Results

1

Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.

Patel SD, Ge Y, Moskalenko M, McArthur JG. Patel SD, et al. Among authors: ge y. J Immunother. 2000 Nov-Dec;23(6):661-8. doi: 10.1097/00002371-200011000-00007. J Immunother. 2000. PMID: 11186154

2

Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.

McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG. McGuinness RP, et al. Among authors: ge y. Hum Gene Ther. 1999 Jan 20;10(2):165-73. doi: 10.1089/10430349950018968. Hum Gene Ther. 1999. PMID: 10022542

3

Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector.

Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG. Tsui LV, et al. Among authors: ge y. Nat Biotechnol. 2002 Jan;20(1):53-7. doi: 10.1038/nbt0102-53. Nat Biotechnol. 2002. PMID: 11753362

4

The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene.

Patel SD, Tran AC, Ge Y, Moskalenko M, Tsui L, Banik G, Tom W, Scott M, Chen L, Van Roey M, Rivkin M, Mendez M, Gyuris J, McArthur JG. Patel SD, et al. Among authors: ge y. Mol Ther. 2000 Aug;2(2):161-9. doi: 10.1006/mthe.2000.0106. Mol Ther. 2000. PMID: 10947944 Free article.

5

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

Ge Y, Powell S, Van Roey M, McArthur JG. Ge Y, et al. Blood. 2001 Jun 15;97(12):3733-7. doi: 10.1182/blood.v97.12.3733. Blood. 2001. PMID: 11389010 Free article.

6

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.

Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC. Ramesh N, et al. Among authors: ge y. Clin Cancer Res. 2006 Jan 1;12(1):305-13. doi: 10.1158/1078-0432.CCR-05-1059. Clin Cancer Res. 2006. PMID: 16397056

7

Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, VanRoey M, Spindler KR, Jooss K. Robinson M, et al. Among authors: ge y. J Virol. 2009 Apr;83(8):3450-62. doi: 10.1128/JVI.02561-08. Epub 2009 Feb 4. J Virol. 2009. PMID: 19193803 Free PMC article.

8

Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.

Robinson M, Ge Y, Ko D, Yendluri S, Laflamme G, Hawkins L, Jooss K. Robinson M, et al. Among authors: ge y. Cancer Gene Ther. 2008 Jan;15(1):9-17. doi: 10.1038/sj.cgt.7701093. Epub 2007 Sep 14. Cancer Gene Ther. 2008. PMID: 17853920

9

Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium.

Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V, Yu DC. Ramesh N, et al. Among authors: ge y. Mol Ther. 2004 Oct;10(4):697-705. doi: 10.1016/j.ymthe.2004.07.002. Mol Ther. 2004. PMID: 15451454 Free article.

10

Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.

Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, Jooss K. Ganesh S, et al. Among authors: ge y. Cancer Gene Ther. 2009 May;16(5):383-92. doi: 10.1038/cgt.2008.90. Epub 2008 Nov 14. Cancer Gene Ther. 2009. PMID: 19011598

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,221 results

Search Page

Filters